KR20100015661A - 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 - Google Patents

암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20100015661A
KR20100015661A KR1020097021695A KR20097021695A KR20100015661A KR 20100015661 A KR20100015661 A KR 20100015661A KR 1020097021695 A KR1020097021695 A KR 1020097021695A KR 20097021695 A KR20097021695 A KR 20097021695A KR 20100015661 A KR20100015661 A KR 20100015661A
Authority
KR
South Korea
Prior art keywords
yeast
cancer
mutant polypeptide
cells
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097021695A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 아펠리안
알렉스 프란츠소프
티모시 씨. 로델
Original Assignee
글로브이뮨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글로브이뮨 filed Critical 글로브이뮨
Publication of KR20100015661A publication Critical patent/KR20100015661A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020097021695A 2007-03-19 2008-01-17 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법 Ceased KR20100015661A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US89568907P 2007-03-19 2007-03-19
US60/895,689 2007-03-19
US91079607P 2007-04-09 2007-04-09
US60/910,796 2007-04-09

Publications (1)

Publication Number Publication Date
KR20100015661A true KR20100015661A (ko) 2010-02-12

Family

ID=39575570

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097021695A Ceased KR20100015661A (ko) 2007-03-19 2008-01-17 암의 표적 치료법의 돌연변이성 이탈의 표적 절제를 위한 조성물 및 방법

Country Status (13)

Country Link
US (1) US8501167B2 (https=)
EP (1) EP2134358A1 (https=)
JP (2) JP5579451B2 (https=)
KR (1) KR20100015661A (https=)
CN (1) CN101730542A (https=)
AU (1) AU2008229295B2 (https=)
BR (1) BRPI0809247A2 (https=)
CA (1) CA2681246A1 (https=)
IL (1) IL201039A0 (https=)
MX (1) MX2009010066A (https=)
NZ (1) NZ580444A (https=)
RU (1) RU2505313C2 (https=)
WO (1) WO2008115610A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR101455222B1 (ko) * 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
WO2008097863A2 (en) * 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
WO2014024965A1 (ja) * 2012-08-10 2014-02-13 学校法人 久留米大学 上皮成長因子受容体のt790m点突然変異配列に由来する抗原ペプチド
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
CN109887553B (zh) * 2019-01-29 2021-01-26 杭州纽安津生物科技有限公司 针对肿瘤靶向药物耐药位点的多肽疫苗及其设计方法
CN116536402B (zh) * 2023-03-08 2025-06-24 华中科技大学同济医学院附属协和医院 Arms-pcr法检测bcr-abl融合基因abl激酶区的核酸组合物、试剂盒

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
US6107457A (en) 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
EP1403283A4 (en) 2001-06-12 2006-05-10 Greenpeptide Co Ltd TUMOR ANTIGEN
DE60232370D1 (de) * 2001-06-14 2009-06-25 Univ California Mutationen in der mit der resistenz gegenüber sti-
JP2005503418A (ja) 2001-09-14 2005-02-03 ユニベルシテ ピエール エ マリー キュリー（パリ シズエム） 治療的ワクチン接種法、ｈｉｖ逆転写酵素の突然変異ペプチドならびにワクチン接種及び診断目的のためのそれらの使用
US20030170851A1 (en) * 2001-10-05 2003-09-11 Christophe Barthe Organic compounds
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
JP4765273B2 (ja) * 2004-06-23 2011-09-07 三菱化学株式会社 ポリエステル系樹脂の分解処理方法
WO2006039533A2 (en) * 2004-09-30 2006-04-13 Sloan Kettering Institure For Cancer Research Bcr-abl imatinib resistance-associated peptides and methods of use thereof
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
US7736642B2 (en) 2006-02-02 2010-06-15 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
BRPI0709340A2 (pt) 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
EP2547792A4 (en) 2010-03-14 2013-11-27 Globeimmune Inc PHARMACOGENOMIC TREATMENT AND ADAPTATION TO THE RESPONSE OF AN INFECTIOUS DISEASE USING YEAST IMMUNOTHERAPY

Also Published As

Publication number Publication date
IL201039A0 (en) 2010-05-17
AU2008229295A1 (en) 2008-09-25
US8501167B2 (en) 2013-08-06
RU2009138327A (ru) 2011-04-27
US20100111912A1 (en) 2010-05-06
JP5579451B2 (ja) 2014-08-27
NZ580444A (en) 2012-02-24
RU2505313C2 (ru) 2014-01-27
WO2008115610A1 (en) 2008-09-25
JP2010522180A (ja) 2010-07-01
BRPI0809247A2 (pt) 2014-09-09
CA2681246A1 (en) 2008-09-25
CN101730542A (zh) 2010-06-09
JP2014156467A (ja) 2014-08-28
AU2008229295B2 (en) 2014-05-22
EP2134358A1 (en) 2009-12-23
MX2009010066A (es) 2009-10-12

Similar Documents

Publication Publication Date Title
US8501167B2 (en) Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
JP2010522180A5 (https=)
AU2009208045B2 (en) Yeast-based vaccines as immunotherapy
US20090010948A1 (en) Anti-tumor vaccines delivered by dendritic cells devoid of interleukin-10
TWI478720B (zh) 對癌症標的療法之脫逃突變種誘發免疫反應之組合物與方法
HK1168046B (en) Yeast-based vaccines as immunotherapy
HK1102022B (en) Yeast-based vaccines as immunotherapy
AU2013231199A1 (en) Yeast-based vaccines as immunotherapy
HK1188944B (en) Yeast-based vaccines as immunotherapy
HK1188944A (en) Yeast-based vaccines as immunotherapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20091016

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20130117

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141226

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20150826

Patent event code: PE09021S02D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150826

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20141226

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I